Canaccord Genuity Downgrades Protalix BioTherapeutics (PLX) to Hold
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.38 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity downgraded Protalix BioTherapeutics (NYSE: PLX) from Buy to Hold, maintains price target of $8.00.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.19 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
- Kepler Cheuvreux Downgrades Avantium N.V (AVTX:NA) to Reduce
- JPMorgan Downgrades Kuaishou Technology (1024:HK) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
